GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Meropenem / vaborbactam (Vabomere)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Both the U.S. label and UCSF use indexed eGFR for this combination. Their printed renal-band boundaries differ: the UCSF bands overlap at 30 and place 50 in a different printed band. Retain the selected source boundary explicitly; do not treat an overlap as an instruction to combine regimens.

Check source scope before reading a dose

UCSF - VABOMERE

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Renal-band endpoints differ between the label mirror and UCSF

Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.

What to reconcile: Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - VABOMERE

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Four grams contains 2 g of each component. Printed columns overlap at exactly 30. Use an adjudicated boundary rather than merging rows.

Total combination amount - IV over 3 hours
Indexed eGFR, mL/min/1.73 m2Source-specific dose / instruction
>504 g every 8 hours
30-502 g every 8 hours
15-302 g every 12 hours
<151 g every 12 hours
Dialysis guidance - separate source-specific schedules
Meropenem/vaborbactam dialysis
Dialysis setting / indicationSource-specific schedule
IHD1 g every 12 hours; one dose after dialysis on HD days
CVVHD2 g every 8 hours
Read the retained text before reformatting

Total combination dosing (4 g contains 2 g of each component), with 3-hour IV infusions:

Indexed eGFR >50 / 30-50 / 15-30 / <15 mL/min/1.73 m2 corresponds to 4 g every 8 hours / 2 g every 8 hours / 2 g every 12 hours / 1 g every 12 hours.

The website columns overlap at exactly 30; select an adjudicated label/institutional boundary rather than blending the two rows.

IHD: 1 g every 12 hours, placing one dose after dialysis on HD days. CVVHD: 2 g every 8 hours.

RDM30-008-meropenem-vaborbactam-1 · Source locator: UCSF - VABOMERE; renal/dosing sections and stated qualifiers

Source-specific limits

The published UCSF renal bands overlap at 30. The exact label is displayed separately.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/meropenem-vaborbactam
Retrieved
2026-09-05
Renal-function method
Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
2959e7ac949a91b4d4d149260ce1f8df090b9798ff43d046b3360caf474f901b

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=meropenem-vaborbactam&s1=RDM30-008-meropenem-vaborbactam&h1=bb1624f2eca6f303afbd96bafa00df405c8d244494ca1c45e8be4ebdb3ed3324